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Background-—We aimed to estimate the prevalence of refractory hypertension (RfH) and to determine the clinical differences
between these patients and resistant hypertensives (RH). Secondly, we assessed the prevalence of white-coat RfH and clinical
differences between true- and white-coat RfH patients.
Methods and Results-—The present analysis was conducted on the Spanish Ambulatory Blood Pressure Monitoring Registry
database containing 70 997 treated hypertensive patients. RH and RfH were deﬁned by the presence of elevated ofﬁce blood
pressure (≥140 and/or 90 mm Hg) in patients treated with at least 3 (RH) and 5 (RfH) antihypertensive drugs. White-coat RfH was
deﬁned by RfH with normal (<130/80 mm Hg) 24-hour blood pressure. A total of 11.972 (16.9%) patients fulﬁlled the standard
criteria of RH, and 955 (1.4%) were considered as having RfH. Compared with RH patients, those with RfH were younger, more
frequently male, and after adjusting for age and sex, had increased prevalence of target organ damage, and previous cardiovascular
disease. The prevalence of white coat RfH was lower than white-coat RH (26.7% versus 37.1%, P<0.001). White-coat RfH, in
comparison with those with true RfH, showed a lower prevalence of both left ventricular hypertrophy (22% versus 29.7%; P=0.018)
and microalbuminuria (28.3% versus 42.9%; P=0.047).
Conclusions-—The prevalence of RfH was low and these patients had a greater cardiovascular risk proﬁle compared with RH. One
out of 4 patients with RfH have normal 24-hour blood pressure and less target organ damage, thus indicating the important role of
ambulatory blood pressure monitoring in guiding antihypertensive therapy in difﬁcult-to-treat patients. ( J Am Heart Assoc.
2017;6:e007365. DOI: 10.1161/JAHA.117.007365.)
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R esistant hypertension (RH) is deﬁned as the persistenceof high blood pressure (BP) ≥140 mm Hg of systolic BP
or ≥90 mm Hg of diastolic BP, despite a therapeutic plan with
3 or more antihypertensive drugs, at the full tolerated doses,
1 of them diuretic, in subjects in whom secondary hyperten-
sion has been ruled out, as well as poor adherence to
antihypertensive therapy.1 Several studies have observed a
prevalence of around 12% to 14% of treated hypertensives.2,3
Compared with subjects with controlled hypertension with 3
or less antihypertensive drugs, patients with RH more
frequently have target organ damage4,5 and a higher
incidence of cardiovascular events.6 We have previously
reported that more than one third of RH patients have normal
24-hour BP (white-coat RH) and they exhibit a better
cardiovascular risk proﬁle compared with those with elevated
24-hour BP.2
The term refractory hypertension (RfH) has been recently
proposed to deﬁne subjects who do not achieve BP control
with 5 or more antihypertensive drugs.7,8 Its prevalence has
been reported to be around 3% of RH subjects, and it has
been associated with male sex, black race, obesity, and a
higher prevalence of cardiovascular and renal alterations.8,9
As in RH, 24-hour ambulatory blood pressure monitoring
(ABPM) is of interest in RfH patients, considering that the
magnitude of the white-coat effect could also be involved in
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RfH. A recent report10 has suggested the white-coat effect
was very uncommon in RfH patients, although results were
based on a small group of patients attending a highly
specialized hypertension clinic. This situation could be
different when examining a broader spectrum of clinical care,
which includes primary care centers.
In the present study, we aimed to assess the prevalence of
RfH and white-coat RfH. Furthermore, we compared clinical
characteristics between RfH and RH patients, as well as
between true and white-coat RfH in a large sample of treated
hypertensive patients seen in real-world (primary care and
specialized hypertension units) clinical practice.
Patients and Methods
The data, analytic methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure.
Study Design
The Spanish Ambulatory BP Monitoring (ABPM) Registry was
initiated in 2004 to promote the use of ABPM in clinical
practice. Details of physician recruitment and characteristics of
the registry have been reported elsewhere.11,12 Brieﬂy, physi-
cians and nurses received speciﬁc training in the technique of
ABPM and used the internet-based platform that receives
ABPM records, together with their corresponding medical
charts. Physicians then obtained a report in real time, and these
registries were stored in the database of an external clinical
research organization. The practice guidelines of the European
Society of Hypertension for BP measurements were used to
establish general indications for ABPM.13,14
The present analysis was conducted on the Spanish ABPM
Registry database containing 70 997 treated patients who
had enough information regarding ofﬁce BP measurements,
ABPM of good quality, and complete clinical information.
Clinical resistant hypertension was considered as an ofﬁce
systolic and diastolic BP ≥140 and/or 90 mm Hg, respec-
tively, despite a prescribed therapeutic schedule with an
appropriate combination of ≥3 antihypertensive drugs, includ-
ing a diuretic. Clinical RfH was considered as an ofﬁce systolic
and diastolic BP ≥140 and/or 90 mm Hg, respectively,
despite a prescribed therapeutic schedule with an appropriate
combination of ≥5 antihypertensive drugs, including a
diuretic. Patients with suspected poor adherence to antihy-
pertensive therapy were excluded, and secondary causes of
hypertension were evaluated according the clinical criteria.
The local Institutional Ethic Committees approved the
study protocol. Written informed consent was obtained from
all participants. The investigation conforms to the principles
outlined in the declaration of Helsinki.
BP Measurements
The methodology of ofﬁce BP measurements and 24-hour
ABPM has been previously described by our group.2,4,11,12
Brieﬂy, BP was measured at the ofﬁce with a calibrated
mercury sphygmomanometer or a validated oscillometric
device, after 5 minutes rest in a sitting position. BP values
were estimated as the mean of 2 readings. Thereafter, 24-hour
ABPM was performed using Spacelabs 90207 automated
noninvasive oscillometric device, programmed to register BP
at 20-minute intervals for the 24-hour period. Valid registries
had to fulﬁll a series of pre-established criteria, including ≥80%
of systolic and diastolic BP successful recordings during the
daytime and nighttime periods, 24-hour duration, and ≥1 BP
measurement per hour. Daytime and nighttime periods were
deﬁned individually according to the patients’ self-reported
data of going-to-bed and getting-up times. Circadian patterns
were deﬁned by calculating night-to-day ratios for systolic and
diastolic BP. According to this, patients were classiﬁed as
systolic or diastolic extreme dippers (night-to-day ratio <0.8),
dippers (night-to-day ratio 0.8–0.9), nondippers (night-to-day
ratio 0.9–1), and risers (night-to-day ratio >1).
Study Variables
Variables of each patient collected from the interview and
physical examination obtained at the routine visit and from
clinical records were deﬁned and measured in accordance
with international guidelines. These included age, sex, weight,
body mass index, duration of hypertension, known cardiovas-
cular risk factors, biochemical values of creatinine, and lipid
proﬁle, target organ damage including urinary albumin
excretion (microalbuminuria deﬁned as values >30 mg/g of
creatinine), ECG (left ventricular hypertrophy deﬁned as a
Clinical Perspective
What Is New?
• The prevalence of the white-coat effect is reported for the
ﬁrst time in a wide sample of refractory hypertensive
patients.
What Are the Clinical Implications?
• One out of 4 patients with refractory hypertension have
normal 24-hour blood pressure measurements and they also
have less target organ damage.
• Ambulatory blood pressure monitoring should be encour-
aged for all subjects not achieving ofﬁce blood pressure
control, as it can help identify patients who will require
additional therapies.
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Sokolow-Lyon voltage >38 mm and/or Cornell duration/
voltage index >2440 mm/ms), and clinical cardiovascular
disease: coronary heart disease, congestive heart failure, or
cerebrovascular disease.15 The estimated glomerular ﬁltration
rate was calculated using the Chronic Kidney Disease-
Epidemiology Collaborative equation.16 Diabetes mellitus
was diagnosed using the medical history if the patient was
under antidiabetic treatment or by 2 or more fasting plasma
glucose determinations ≥7.0 mmol/L (126 mg/dL). Dyslipi-
demia was considered to be present if patients were being
treated with lipid-lowering drugs and/or total cholesterol was
>5 mmol/L (190 mg/dL), low-density lipoprotein cholesterol
was >3.0 mmol/L (115 mg/dL), high-density lipoprotein
cholesterol was <1.0 mmol/L (40 mg/dL) in men or
<1.2 mmol/L (46 mg/dL) in women, or triglycerides were
>1.7 mmol/L (150 mg/dL). Moreover, details about antihy-
pertensive treatment (including number and types of drugs)
were also collected.
Statistical Analysis
Data are presented as absolute frequencies and percentages
for qualitative variables and as mean (SD) or median
(interquartile range) for quantitative variables. Differences in
study variables between groups were assessed with the
Pearson v2 test for qualitative variables and the Student t test
(or Mann–Whitney test) for quantitative data. In addition,
general linear models for quantitative variables and multiple
logistic regression for qualitative variables were used for the
assessment of differences after adjusting for age and sex. The
SPSS Windows version 19.0 software (SPSS Inc, Chicago, IL)
was used for statistical analysis.
Results
A total of 11 972 (16.9%) patients fulﬁlled the standard
criteria of RH (ofﬁce systolic blood pressure ≥140 and/or
diastolic blood pressure ≥90 mm Hg despite the use of ≥3
antihypertensive drugs), and 955 (7.9% of RH; 1.4% of the
entire treated group) were considered as having RfH (elevated
ofﬁce BP despite the simultaneous use of 5 or more
antihypertensive agents).
Compared with RH, patients with RfH were younger, more
frequently males, had a longer duration of hypertension, and
higher prevalence of obesity, diabetes mellitus, and dyslipi-
demia. The prevalence of chronic kidney disease (estimated
glomerular ﬁltration rate <60 mL/min per 1.73 m2) was also
higher in RfH patients. Regarding organ damage, after
adjusting for age and sex, microalbuminuria, ECG-based left
ventricular hypertrophy and previous history of a cardiovas-
cular event were also signiﬁcantly higher in RfH, compared
with RH patients (Table 1).
All groups of antihypertensive drugs were more commonly
used in RfH versus RH patients, including mineralocorticoid
receptor antagonists, which amounted to 11.5% of RfH
(n=111; 88 with spironolactone and 22 with eplerenone),
and to 1.4% in RH (P<0.001 for the comparison between
groups) (Table 2).
Table 1. Clinical Features in RfHs in Comparison With RH Subjects
RfH (n=955) RH (n=11 017) P Value
P Adjusted for
Age and Sex
Age, y 63.9 (11.0) 64.9 (11.6) 0.007
Sex, % men 56.3 51.3 0.003
Duration hypertension, y 13.3 (9.2) 10.9 (8.5) <0.001 <0.001
BMI, kg/m2 31.6 (4.8) 30.7 (4.8) <0.001 <0.001
Obesity (BMI ≥30), % 59.6 51.4 <0.001 <0.001
Diabetes mellitus, % 48.1 33.5 <0.001 <0.001
Smokers, % 15.1 12.9 0.056 0.290
Dyslipidemia, % 61.9 51.7 <0.001 <0.001
LVH by ECG, % 27.6 14.9 <0.001 <0.001
Serum creatinine, mg/dL 1.20 (0.69) 1.02 (0.42) <0.001 <0.001
eGFR <60 mL/min per 1.73 m2, % 32.1 23.6 <0.001 <0.001
UAE, mg/g 14.2 [4–58.5] 8.9 [3.3–28] <0.005 0.101
UAE ≥30 mg/g, % 38.3 24.5 <0.001 <0.001
Previous cardiovascular disease, % 20.5 14.7 <0.001 <0.001
Values are mean (SD) or median [interquartile range]. BMI indicates body mass index; eGFR, estimated glomerular ﬁltration rate; LVH, left ventricular hypertrophy; RfH, refractory
hypertension; RH, resistant hypertension; UAE, urinary albumin excretion.
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Table 3 shows ofﬁce and ambulatory BP values in patients
with RfH and RH. After adjusting for age and sex, the former
group had signiﬁcantly higher values for ofﬁce, 24-hour,
daytime and nighttime systolic BP, and for nighttime diastolic
BP. RfH was also associated with higher night-to-day ratios for
both systolic and diastolic BP. As a consequence, the
proportion of reduced dippers/risers was increased in RfH,
compared with RH patients (P<0.001 for both systolic and
diastolic pattern distribution) (Figure).
A total of 255 patients among 955 with RfH (26.7%) had
normal 24-hour BP (<130/80 mm Hg). The prevalence of
white-coat RfH was signiﬁcantly lower when compared with
RH (37.1% with normal 24-hour BP; P<0.001). When compar-
ing patients with true, versus white-coat RfH (Table 4), the
former group were more frequently males, with a longer
duration of hypertension, and more frequently had left
ventricular hypertrophy on ECG or microalbuminuria.
Discussion
The main ﬁndings of the present study were, ﬁrstly, that the
prevalence of this particular phenotype of RfH was low (1.4%
of treated hypertensive) but still accounts for a signiﬁcant part
of the population of RH (7.9%). Secondly, cardiovascular risk
was higher in the group of RfH in comparison to RH. Thirdly,
the prevalence of white-coat RfH was lower than the
prevalence of white-coat RH, but still high: 26.7% of them
had a 24-hour controlled BP, and fourthly, white-coat RfH was
associated with less target organ damage, compared with RfH
with elevated 24-hour BP.
In the present study, only 1.4% of treated hypertensive
patients had RfH. The prevalence of RfH observed in the
participants in the REGARD (Reasons for Geographic And
Racial Differences in Stroke) Study was even lower (0.5%).8 In
the present study, 7.9% of RH had RfH. Dudenbostel et al9,17
reported that the prevalence of RfH in a referral hypertension
Table 2. Antihypertensive Drug Classes in Patients With RfH
or RH
Drug Class RfH RH P Value
Diuretics* 100% 100%
RAS blockers 99.4% 95.5% <0.001
CCB 84.9% 58.3% <0.001
b-Blockers 77.2% 43.0% <0.001
a-Blockers 62.4% 17.4% <0.001
Central blocking agents 12.1% 1.4% <0.001
Aldosterone antagonists 11.5% 1.4% <0.001
Vasodilators 2.2% 0.2% <0.001
Central blocking agents include clonidine, moxonidine, reserpine, and a-methyldopa.
Vasodilators include hydralazine and minoxidil. ACE indicates angiotensin-converting
enzyme; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; RAS,
renin–angiotensin system; RfH, refractory hypertension; RH, resistant hypertension.
*Required for deﬁnition. RAS blockers include ACE inhibitors, ARB, and aliskiren.
Table 3. Differences in Ofﬁce, 24-H, Daytime, and Nighttime
BP, as Well as Night-to-Day Ratios, in Patients With RfH
Compared With RHs
RfH (n=955) RH (n=11 017) P Value
P Adjusted
for Age
and Sex
Office
systolic BP
164.8 (19.3) 160.8 (17.3) <0.001 <0.001
Office
diastolic BP
87.8 (13.7) 88.1 (12.2) 0.645 0.093
24-h
systolic BP
139.7 (17.4) 134.2 (15.7) <0.001 <0.001
24-h
diastolic BP
75.2 (12.5) 74.5 (11.2) 0.122 0.885
Daytime
systolic BP
141.6 (17.5) 136.7 (15.9) <0.001 <0.001
Daytime
diastolic BP
77.2 (13.1) 76.9 (11.7) 0.580 0.274
Nighttime
systolic BP
134.2 (20.5) 126.9 (18.0) <0.001 <0.001
Nighttime
diastolic BP
69.5 (12.6) 67.8 (11.1) <0.001 0.001
Systolic
BP night/day
ratio
0.95 (0.09) 0.93 (0.09) <0.001 <0.001
Diastolic
BP night/day
ratio
0.90 (0.10) 0.88 (0.09) <0.001 <0.001
Values are mean (SD). BP indicates blood pressure; RfH, refractory hypertension; RH,
resistant hypertension.
Refractory Resistant
Figure. Distribution of circadian patterns in refractory and
resistant hypertensive patients. The former group has a higher
proportion of reduced dippers and risers for both systolic and
diastolic BP (P<0.001 for both comparisons). BP indicates blood
pressure.
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unit was 5%, and Calhoun et al8 estimated a prevalence of
RfH of 3.6% of subjects with controlled or uncontrolled RH.
The slightly higher prevalence observed in our study could be
explained by 2 reasons: ﬁrst, because low BP control is one of
the main indications for ABPM, it is possible that the Spanish
Registry was selecting more subjects with difﬁcult-to-treat
hypertension than other population-based studies. Secondly,
the prevalence of RfH depends critically on the deﬁnition
used, and thus our study may have overestimated the actual
prevalence because in our deﬁnition we did not speciﬁcally
require the mandatory use of chlorthalidone and spironolac-
tone, which are associated with higher BP control rates.9 In
fact, it is noteworthy that only 11% of our patients were
treated with mineralocorticoid receptor antagonists. The use
of this drug in RfH observed by Calhoun et al8 was higher
(18%), but still lower than expected. A meta-analysis of
studies in which mineralocorticoid receptor antagonists with
or without random allocation were used has shown that low-
dose spironolactone is an effective and safe additional drug to
achieve BP control in many RH patients, although it is required
that renal function is preserved, or only slightly or moderately
reduced.18 The results of the PATHWAY-2 (The Prevention and
Treatment of Hypertension With Algorithm based therapy)
study,19 the ﬁrst randomized study evaluating different
therapeutic options (spironolactone, doxazosin, bisoprolol, or
placebo) as the fourth step in the management of patients
with RH, have unequivocally demonstrated that spironolac-
tone is the best option, at least in the short term, to improve
BP control in RH subjects. The open-label, randomized clinical
trial DENERVHTA (DENERVación en HiperTensión Arterial)
study20 has shown that allocation to spironolactone treatment
(25–50 mg daily) in true RH subjects was more effective in
reducing systolic and diastolic 24-hour BP than renal dener-
vation. These results support that, except if a contraindication
exists, mineralocorticoid receptor antagonists should be
included in the therapeutic regimen of subjects with RH.
This phenotype of RfH shares some similarities but also
some differences with respect to subjects with RH. In our study,
patients with RfH had a signiﬁcantly higher prevalence of
diabetes mellitus, obesity, target organ damage, and previous
history of cardiovascular disease, as well as a longer duration of
hypertension, as previously reported by other authors.8,21
Differences between RfH and RH go in the same direction
as those observed when comparing RH versus controlled
patients,4 thus suggesting that, when markedly present, the
same characteristics leading to RH would be responsible for
treatment failure and development of RfH, as an extreme
phenotype.9
Another important novel feature in RfH patients is the
worse circadian proﬁle in comparison to RH. Not only are
ofﬁce and ambulatory systolic blood pressure higher, but also
differences are more important in nighttime BP, and the
nocturnal decline in BP is lower. Both nocturnal BP elevation
and reduced nocturnal dipping have been associated with
increased prevalence of target organ damage and a worse
cardiovascular outcome in patients with RH.22–24
We have also reported here that 1 out of 4 RfH patients in
the present study show normal 24-hour BP, suggesting that
the white-coat effect accounts for a quite high rate of
patients with apparent treatment failure. Although its preva-
lence was considerably lower than that of RH,2 it is
surprising that those patients were still receiving 5 or more
drugs based only on clinic BP, without considering ABPM in
earlier steps of management. A recent report10 has found
that normal ABPM of RfH was present only in 2 out of 31
patients with RfH. Besides differences in sample size,
discrepancies between studies are probably derived from
patients’ origin, a highly specialized clinic in the report from
Siddiqui and coworkers10 and a nationwide Registry in the
current report. We can speculate that perhaps a previous
normal ABPM has prevented an increase in antihypertensive
treatment in patients attending a specialized hypertension
clinic, thus selecting only those with a true resistance to 5
drugs. In addition, the report from Siddiqui et al10 used
automated ofﬁce BP monitoring, which has been claimed to
results in lower values than daytime BP obtained through
ABPM.25 In contrast, our data derive from the implementa-
tion of ABPM in clinical settings where this tool was
Table 4. Clinical Features in RfHs With or Without Elevated
24-H BP
True RfH
(n=700)
White-Coat
RfH (n=255) P Value
Age, y 63.9 (11.0) 63.9 (10.7) 0.984
Sex, % men 58.4 50.6 0.033
Duration hypertension, y 13.7 (9.2) 12.3 (9.3) 0.040
BMI, kg/m2 31.6 (4.9) 31.5 (4.8) 0.703
Obesity (BMI ≥30), % 60.1 58.0 0.602
Diabetes mellitus, % 48.9 45.9 0.422
Smokers, % 16.3 11.8 0.102
Dyslipidemia, % 63.7 56.9 0.060
LVH by ECG, % 29.7 22.0 0.018
eGFR <60 mL/min
per 1.73 m2, %
32.0 32.2 0.962
Serum creatinine, mg/dL 1.21 (0.69) 1.16 (0.66) 0.475
UAE, mg/g 16.8 [5.0–99.0] 8.0 [3.1–32] 0.010
UAE ≥30 mg/g, % 42.9 28.3 0.047
Previous cardiovascular
disease, %
20.6 20.4 0.952
Values are mean (SD) or median [interquartile range]. BMI indicates body mass index; BP,
blood pressure; eGFR, estimated glomerular ﬁltration rate; LVH, left ventricular
hypertrophy; RfH, refractory hypertension; UAE, urinary albumin excretion.
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previously unavailable. We can also speculate that most
patients were uptitrated to 5 or more antihypertensive drugs
without considering ABPM.
Differences in ambulatory in RfH were associated with
differences in the cardiovascular risk proﬁle, as left ventricular
hypertrophy and microalbuminuria were more common in
true- versus white-coat RfH patients. It seems reasonable to
advocate for ABPM to guide therapeutic decisions, at least in
those patients not achieving BP control with 3 antihyperten-
sive drugs.
Our study has some limitations. First, it is a cross-sectional
study that allows only descriptive associations, but this was
the main objective of the present report; secondly, like other
registries, the Spanish registry was not directly focused on
RfH.
Another limitation we must mention is that the diagnosis of
RH or RfH is probable, but not absolutely conﬁrmed, since we
cannot ensure that all secondary causes of hypertension have
been discarded in such a large database, not just the
suboptimal adherence. We must remark that according to
the study-accepted deﬁnition, the criterion used to deﬁne
refractory hypertension required the use of a diuretic, but not
necessarily a mineralocorticoid receptor antagonist. Most
patients were included in this database before the publication
of the results of the PATHWAY-2 Study.19 Certainly, in the light
of recent evidence, the percentage of patients with noncon-
trolled BP that receive a mineralocorticoid receptor antagonist
in our cohort is low. In addition, only whites have been included
in the present study, and our results cannot be extrapolated to
other populations; other previous studies have shown that RfH
was more common among patients of black ancestry.8
In conclusion, 1.4% of treated hypertensive patients are
not controlled even they are treated with 5 or more
antihypertensive drugs. These RfH patients, in comparison
to RH, have some distinctive clinical features of a worse
cardiovascular risk proﬁle and more target organ damage,
probably associated with higher ambulatory BP and more
pronounced circadian alterations. One in 4 RfH patients have
normal 24-hour BP (white-coat RfH) also exhibiting less organ
damage than those with true RfH. Our ﬁndings are relevant for
clinical practice because given the magnitude of white-coat
RfH, physicians should be aware of avoiding overdiagnosing
and overtreating these patients, based only on clinic BP if the
decisions rely exclusively on clinic BP. Standardized repeated
BP measurement obtained by patients at home during several
days has also been recommended in clinical practice, but in
patients with RH and RfH 24-hour ABPM is more reliable and
also provides relevant information about nighttime BP and
circadian pattern. Moreover, given the low use of the
effective-proven mineralocorticoid antagonist receptor drugs
in RfH, a large room for improvement in BP control remains as
a simple, reasonable perspective.
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